Active, not recruitingNot applicableNCT02828618
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AGO Study Group
- Principal Investigator
- Sven Mahner, Professor MD, MDAGO Study Group
- Intervention
- PDS (Primary Debulkdung Surgery)(procedure)
- Enrollment
- 797 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2025
Study locations (20)
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Medical University of Vienna, Vienna, Austria
- University Hospital, Rigshospitalet, Copenhagen, Denmark
- Institut Bergonié, Bordeaux, France
- Hôpital Européen Georges Pompidou (HEGP), Paris, France
- Institute Gustave Roussy, Villejuif, France
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Germany
- Universitätsklinikum Carl Gustav Carus Dresden, Klinik & Poliklinik f. Frauenheilkunde & Geburtshilfe, Dresden, Germany
- Kaiserswerther Diakonie; Florence-Nightingale-Hospital, Düsseldorf, Germany
- Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gyn. Onkologie, Essen, Germany
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Germany
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, München, Germany
- Klinikum rechts der Isar, Frauen- und Poliklinik, München, Germany
- Universitätsklinikum Tübingen, Tübingen, Germany
- European Institute of Oncology; Gynecologic Cancer Surgery, Milan, Italy
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02828618 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT07544030A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancertongweihua